Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands

Dendritic cell (DC) vaccines have proven to be a valuable tool in cancer immune therapy. With several DC vaccines being currently tested in clinical trials, knowledge about their therapeutic value has been significantly increased in the past decade. Despite their established safety, it has become cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Versteven, Maarten, Flumens, Donovan, Campillo-Davó, Diana, De Reu, Hans, Van Bruggen, Laura, Peeters, Stefanie, Van Tendeloo, Viggo, Berneman, Zwi, Dolstra, Harry, Anguille, Sébastien, Hobo, Willemijn, Smits, Evelien, Lion, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891487/
https://www.ncbi.nlm.nih.gov/pubmed/35250967
http://dx.doi.org/10.3389/fimmu.2022.734256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891487/
https://www.ncbi.nlm.nih.gov/pubmed/35250967
http://dx.doi.org/10.3389/fimmu.2022.734256

Ejemplares similares